
51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
🔥 0 minutes ago
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
• Develop and execute a global training strategy tailored to cell therapy programs across clinical and commercial stages • Build role-specific onboarding, certification, and continuous learning pathways for Medical and Commercial teams • Design and develop training content while overseeing and leveraging external vendors • Deliver training on disease state education, unmet medical needs, CAR T product design and manufacturing, clinical data, safety monitoring and management, and competitive landscape • Plan and lead virtual and onsite onboarding and refresher programs • Partner cross-functionally with Medical Affairs, Clinical Development, CMC, Regulatory, Quality, Commercial, and Patient Services • Ensure training materials and certification processes meet FDA, EMA, and global compliance standards • Develop learning systems and training analytics, including KPIs for competency, certification, and launch preparedness • Partner with HR on company-wide onboarding programs for new employee orientation
• Advanced degree required (APN, PharmD, PhD, MD, or equivalent) • 10+ years in biotechnology or pharmaceutical industry • Minimum 5 years in Medical Affairs leadership or Medical Training roles • Direct experience in cell therapy and/or gene therapy strongly preferred • Neuroscience, neurology, and/or immunology experience strongly preferred • Experience supporting launch of advanced therapies strongly preferred • Strong knowledge of regulatory and compliance frameworks in advanced modalities • Demonstrated ability to build infrastructure in clinical-stage or scaling biotech environments • Excellent communication skills, cross-functional partnership, and ability to manage complexity in fast-paced, resource-conscious environments
• Eligible for bonus • Benefits • Participation in Company’s stock plan • Approximately 15% travel
Apply Now🔥 17 hours ago
National Facilities Director overseeing ClearSky Health’s hospital infrastructure, Environment of Care, and regulatory compliance. Leading modernization, safety, emergency preparedness, and facilities leadership across multiple healthcare locations.
🔥 17 hours ago
Director advising Calix Product leaders on AI-driven talent, organizational design, and workforce strategy. Supporting innovation and growth for a cloud-first broadband technology platform.
🇺🇸 United States – Remote
💵 $144k - $294.4k / year
💰 $50M Venture Round on 2009-08
⏰ Full Time
🔴 Lead
👔 Director
🦅 H1B Visa Sponsor
🔥 23 hours ago
Institutional BD Director expanding Particula’s digital-asset ratings and monitoring platform. Building enterprise partnerships across exchanges, financial institutions, and tokenized-asset infrastructure.
🕒 Yesterday
Group Patient Care Director leading veterinary technician and assistant teams across VCA Animal Hospitals. Improving patient safety, clinical quality, associate development, and hospital performance across the North Atlantic region.
🕒 Yesterday
Software product marketing leader advancing Varsity Yearbook tools for schools nationwide. Owning roadmaps, launches, customer enablement, and field adoption of digital solutions.